Maia Biotechnology wins $2.3 million NIH grant for Phase 2 NSCLC trial expansion

• Maia Biotechnology secured FDA clearance for an amended IND for ateganosine, citing improved manufacturing capabilities and efficiencies.
• The NIH awarded Maia a USD 2.3 million grant to fund a U.S. Phase 2 expansion in third-line non-small cell lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609160815PRIMZONEFULLFEED9827717) on September 16, 2026, and is solely responsible for the information contained therein.